Botulinum TOX TYP a 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTLT
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,876
Award facts
- Contract value 100% obligated
- $14,875.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $14,875.97 for Botulinum Toxin Type A 1S on January 15, 2026, with completion scheduled for February 4, 2026. The contract represents a firm fixed-price delivery order issued by the Defense Logistics Agency without set-aside designation, leveraging DMS Pharmaceutical Group's established capability as a critical supplier within the federal pharmaceutical supply chain. This delivery order falls under the company's broader single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a contract designated SPE2DR with a $499,999,999 ceiling value and completion date of December 31, 2036.
The PPV-G GEN V program, part of the Department of Defense's $30.3 billion pharmaceutical procurement strategy, authorizes the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's appointment as a regional prime vendor contractor under this initiative reflects the company's demonstrated performance in supplying specialized pharmaceutical requirements to federal military medical systems, with the company maintaining no identified subcontractor relationships in its award documentation. The firm fixed-price structure and absence of set-aside designation indicate the company's competitive standing in unrestricted federal pharmaceutical procurement.
Quick answers
Who was awarded contract SPE2DR26FBTLT?
SPE2DR26FBTLT was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FBTLT worth?
The government has obligated $14,876 on SPE2DR26FBTLT.
Is contract SPE2DR26FBTLT an order under another contract?
Yes. SPE2DR26FBTLT is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTLT competed?
The extent of competition for SPE2DR26FBTLT was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award